Congrats to our consumer representative, Ms Janne Williams👏 She was awarded the SPHPM Consumer Excellence Award🌟 in recognition of her impact on multiple academic projects, including LaRDR! @ericawood.bsky.social #LymphomaResearch #Registry

@lardr.bsky.social is co-hosting a breakfast meeting on Tuesday, 28 October, at 7 am AWST with the Australasian Lymphoma Alliance & Lymphoma Australia! Walk-ins to room M1 at the Perth Convention & Exhibition Centre and online attendance (link below) are welcome! us06web.zoom.us/w/8786927032...

Our registry bulk study has been interviewed by Oncology Republic 📰 'Lymphoma bulk: why size doesn’t always matter' @elizahawkes.bsky.social @ericawood.bsky.social @allibarraclough.bsky.social #Registry #LymphomaResearch #ClinicalResearch

⭐️⭐️⭐️ The 9500th participant ⭐️⭐️⭐️was recruited to the Lymphoma and Related Diseases Registry! Congratulations and thanks to all participants, participating sites and staff, principal investigators and supporters.

📣 Register now for the hybrid Lymphoma Breakfast Meeting! Join us online to hear updates on our work, presented alongside the Australian Lymphoma Alliance and Lymphoma Australia. 🥐☕ Breakfast will be provided for on-site attendees.

We're also showcasing our #18ICML posters: -221, real-world data on end-of-treatment imaging #TCellLymphoma; -390, Ki67 expression level in #FollicularLymphoma See you June 18👋 @icmlugano.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social #LymphomaResearch #ClinicalResearch #Registry

Thanks to all who stopped by to chat with us at our #FollicularLymphoma #EHA2025 poster 👋 @hemasphere-journal.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social #LymphomaResearch #ClinicalResearch #Registry

We're excited to meet you at our #EHA2025 poster PS1885 to talk about the study of Ki67 expression in Australasian #FollicularLymphoma patients. See you Saturday, June 14 👋 @hemasphere-journal.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social #LymphomaResearch #ClinicalResearch #Registry

Catch up on our latest newsletter 📰 sway.cloud.microsoft/TCxuAWeWloXztORw?ref=Link For our previous news and updates, visit lardr.org/newsletter

The Lymphoma and Related Diseases Registry enrolled the ⭐9000th⭐ participant on May 8, 2025! We would like to express our sincere gratitude to all participants, participating sites and staff, principal investigators and industry partners for their continued support of the registry 🙌

LaRDR provides #research 🔍 opportunities for #lymphoma & #CLL investigators and fellows in regional/rural hospitals🏥across Australia and New Zealand 🌏 Tune in to this interview to hear more from Dr Wight! 🎬 youtu.be/3csUYJsZkZs

LaRDR supports early-career clinician-researchers by providing #research opportunities📊. They gain experience in manuscript writing ✍️ for publication and conference presentations. Tune in to this interview to hear more from Dr Wang! 🎬 youtu.be/0rjytiYHhuY

LaRDR partners with international researchers to conduct #lymphoma & #CLL #research and report on multi-centre data🌍 Tune in to this interview to hear more from Dr Viiala! 🎬 youtu.be/4iO__sHQr6A

LaRDR supports investigator-initiated studies utilising #registry data. Our collaborations facilitate #academic real-world #research ✏️ Tune in to this interview with Dr @baggydi.bsky.social! 🎬 youtu.be/vnOPIN-NOEg

LaRDR collects high-quality data to conduct #lymphoma #research and monitor patient treatment outcomes.📚 We also provide ongoing data management training for the site study coordinators. 📝 Tune in to this interview with Dr @allibarraclough.bsky.social 🎬https://youtu.be/pbpHYVraHgA

LaRDR is a national #registry with sites in Australia & New Zealand. We report on patient treatments & outcomes in #lymphoma care. We also support real-world #research.📄 Tune in to this interview with Prof Opat! 🎬 youtu.be/HRLTZEyITn0